Treatment experience of intractable headache in patients with growth hormone ⁃ secreting pituitary adenoma

• Main Authors: Yi⁃ding FENG, Kan DENG, Ren⁃zhi WANG
• Format: Article
• Language: English
• Published: Tianjin Huanhu Hospital 2020-03-01
• Series: Chinese Journal of Contemporary Neurology and Neurosurgery
• Subjects: pituitary neoplasms; growth hormone ⁃ secreting pituitary adenoma; acromegaly; headache; somatostatin
• Online Access: http://www.cjcnn.org/index.php/cjcnn/article/view/2102

Background Headache is a common complaint in growth hormone (GH) ⁃ secreting pituitary adenoma and considered to be relieved after tumor removed. However, some headache could be resistant after surgery, which is rare and intractable. This article summarized the clinical characteristics and diagnosis and treatment of intractable headache combined with GH ⁃ secreting pituitary adenoma. Methods and Results Four intractable headache combined with GH ⁃ secreting pituitary adenoma patients hospitalized in Peking Union Medical College Hospital from Febuary 2014 to July 2017 were reviewed. All the 4 patients received transsphenoidal surgery again and took long ⁃ acting somatostatin analogs (SSTAs) to control headache symptoms after admission. The serum GH, insulin ⁃ like growth factor ⁃ 1 (IGF ⁃ 1) and GH in Oral Glucose Tolerance Test (OGTT) before surgery were (5.80 ± 2.86) , (644 ± 249) and (3.12 ± 1.37) μg/L, (3.50 ± 2.91), (362.25 ± 160.11) and (3.28 ± 2.99) μg/L in 7 days after surgery, and (3.10 ± 2.14), (357 ± 165) and (1.54 ± 1.24) μg/L 3 months after surgery. Numeric Rating Scale(NRS) was (7.50 ± 0.58), (1.75 ± 0.50) and (3.75 ± 1.50) score in different timepoints. Conclusions Long ⁃ acting SSTAs can be effective to intractable headache combined with GH⁃secreting pituitary adenoma, further studies are needed. DOI：10.3969/j.issn.1672⁃6731.2020.03.010